As soon as Phase 3 results were published, Israel added the new combo-therapy of venetoclax and azacytidine from global biotech AbbVie to the basket of treatments for acute myeloid leukemia (AML). Israel had the most patients enrolled in the Phase 3 study.
Israel is first to approve new AML cancer treatment
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.